Somapacitan0 vendors competing
No vendor pricing available for this peptide yet.
Research details
Somapacitan — research data
Regulatory statusFDA-approved (Sogroya)
NCAA D1Banned
Overview
About Somapacitan
Mechanism of action
Long-acting recombinant GH with albumin-binding fatty acid
Safety profile
Peripheral edema, arthralgia, glucose intolerance · Approved adult GH deficiency; weekly injection; well-characterized; similar safety to daily GH
Related pages